Praxis Precision Medicines, Inc. PRAX Number of performance obligations
Number of performance obligations at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept prax:NumberOfPerformanceObligations.
The source filing: Praxis Precision Medicines, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001689548-26-000083
The Company’s obligations under the arrangement comprise a single promise, or one performance obligation, related to the exclusive development and commercialization license granted to Tenacia. Total proceeds associated with the combined arrangement at inception were $14.8 million consisting of the following: (i) $10.0 million gross proceeds from the sale of common stock under the Stock Purchase Agreement and (ii) $4.8 million, net of tax, related to the up-front payment under the Tenacia License Agreement, both of which were received in January 2024. During the three and six months ended June 30, 2026 and 2025, the Company had not achieved any development or sales milestones or earned any royalties under the Tenacia License Agreement.
Item 1. Financial Statements (Unaudited)
FAQ
- What is Praxis Precision Medicines, Inc.'s number of performance obligations?
- Praxis Precision Medicines, Inc. (PRAX) reported number of performance obligations of $1 in Q4 2023.
- What does number of performance obligations mean?
- Number of performance obligations as reported by Praxis Precision Medicines, Inc. Common Stock.
Ask your AI about Praxis Precision Medicines, Inc.'s number of performance obligations.
Connect your AI assistant and compare it to peers, right in your chat.
